SAN ANTONIO — A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer. pCR, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results